Targeted drugs for systemic therapy of lung cancer with brain metastases.

about

Predicting Outcomes From Radical Radiotherapy for Non-small Cell Lung Cancer: A Systematic Review of the Existing Literature

P2860

Q58576082-73840D8E-198F-48EE-AE25-521752A458BC

P2860

Targeted drugs for systemic therapy of lung cancer with brain metastases.

Item

http://www.wikidata.org/entity/Q50052820

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Targeted drugs for systemic therapy of lung cancer with brain metastases.

@en

Targeted drugs for systemic therapy of lung cancer with brain metastases.

@nl

type

Item

label

Targeted drugs for systemic therapy of lung cancer with brain metastases.

@en

Targeted drugs for systemic therapy of lung cancer with brain metastases.

@nl

prefLabel

Targeted drugs for systemic therapy of lung cancer with brain metastases.

@en

Targeted drugs for systemic therapy of lung cancer with brain metastases.

@nl

P1476

Targeted drugs for systemic therapy of lung cancer with brain metastases.

@en

P2093

Jian Xu

http://www.w3.org/2001/XMLSchema#string

Jun Zhou

http://www.w3.org/2001/XMLSchema#string

Wen-Juan Liu

http://www.w3.org/2001/XMLSchema#string

Ya-Wen Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Cancer statistics, 2016

P304

5459-5472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.23616

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29435193

http://www.w3.org/2001/XMLSchema#string

P932

5797064

http://www.w3.org/2001/XMLSchema#string

Targeted drugs for systemic therapy of lung cancer with brain metastases.

about

P2860

P2860

Targeted drugs for systemic therapy of lung cancer with brain metastases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932